Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer

Official Title

MVA-BN Imvamune Smallpox Vaccine Virus for Treatment of Basal Cell Carcinoma, Squamous Cell Carcinomas


This study examines the safety and efficacy of using the Imvamune smallpox vaccine in the treatment of non-melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma).

Trial Description

Primary Outcome:

  • Maximum Tolerated Dose (MTD)
  • Objective Tumour Response Rate (ORR)
Secondary Outcome:
  • Viral load in NMSC tumours
  • Number of T cells/concentration of antigen specific antibodies
One of the main ways cancer is able to develop is by hiding or evading our immune system which usually detects and kills potential tumour cells. Once cancer has developed the ability to evade the immune system it can continue to grow and become a tumour. One potential strategy currently being researched, called immunotherapy, uses viruses to stimulate an immune response which attacks the tumour. Imvamune is a live, non-replicating virus used in Canada to vaccinate adults and children against smallpox. It is safe to use in immunosuppressed patients because the virus is unable to replicate and spread past the first infected cell. This makes the Imvamune vaccine a viable candidate for immunotherapy in immunosuppressed patients who are at a much higher (up to 60x) risk of developing non-melanoma skin cancers.

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society